Anti-tumor necrosis factor agents in Crohn's disease and ulcerative colitis: Beyond luminal disease

被引：3
|
作者：
Nunez-Gomez, Laura [1 ]
Mesonero-Gismero, Francisco [1 ]
Albillos-Martinez, Agustin [1 ]
Lopez-Sanroman, Antonio [1 ]
机构：
[1] Hosp Univ Ramon y Cajal, Serv Gastroenterol & Hepatol, Madrid, Spain
来源：
GASTROENTEROLOGIA Y HEPATOLOGIA | 2018年 / 41卷 / 09期
关键词：
Inflammatory bowel disease; Crohn's disease; Ulcerative colitis; Anti-TNF; EVIDENCE-BASED CONSENSUS; INFLAMMATORY-BOWEL-DISEASE; ANTI-TNF THERAPY; EXTRAINTESTINAL MANIFESTATIONS; CLINICAL CHARACTERISTICS; PYODERMA-GANGRENOSUM; FACTOR ANTAGONISTS; NATURAL-HISTORY; INFLIXIMAB; FISTULAS;
D O I：
10.1016/j.gastrohep.2018.06.010
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Anti-tumor necrosis factor agents (anti-TNF) drugs are commonly used in patients with inflammatory bowel disease (IBD) and have proven effective in both induction and maintenance therapy in luminal Crohn's disease and ulcerative colitis. Their efficacy has also been proven in fistulising perianal Crohn's disease. However, the evidence in other scenarios, such as stricturing, penetrating and non-fistulising perianal Crohn's disease, extraintestinal IBD manifestations and ileoanal reservoir complications, is not as robust. The aim of this review was to perform an analysis of the available literature and to determine the rote of anti-TNF drugs in common clinical practice in patients affected by these complications. (C) 2018 Elsevier Espana, S.L.U. All rights reserved.
引用
收藏
页码：576 / 582
页数：7
相关论文
共 50 条
  • [41] Anti-tumor Necrosis Factor Therapy for Crohn Disease: Friend or Foe to the Surgeon?
    Kim, Hungdai
    ANNALS OF COLOPROCTOLOGY, 2015, 31 (04) : 121 - 122
  • [42] Efficacy of infliximab for luminal and fistulizing Crohn's disease and in ulcerative colitis
    Behm B.W.
    Bickston S.J.
    Current Treatment Options in Gastroenterology, 2007, 10 (3) : 171 - 177
  • [43] SAFETY OF ANTI-TUMOR NECROSIS FACTOR AGENTS COMPARED TO USTEKINUMAB AND VEDOLIZUMAB IN ELDERLY PATIENTS WITH ULCERATIVE COLITIS
    Chaaban, Lara
    Huang, Jane
    Melia, Joanna
    GASTROENTEROLOGY, 2024, 166 (03) : S115 - S115
  • [44] SAFETY OF ANTI-TUMOR NECROSIS FACTOR AGENTS COMPARED TO USTEKINUMAB AND VEDOLIZUMAB IN ELDERLY PATIENTS WITH ULCERATIVE COLITIS
    Chaaban, Lara
    Huang, Jane
    Melia, Joanna
    INFLAMMATORY BOWEL DISEASES, 2024, 30 : S82 - S83
  • [45] Long-Term Efficacy of Anti-Tumor Necrosis Factor Agents in Pediatric Luminal Crohn's Disease: A Systematic Review of Real-World Evidence Studies
    van Rheenen, Hanna
    van Rheenen, Patrick Ferry
    PEDIATRIC GASTROENTEROLOGY HEPATOLOGY & NUTRITION, 2020, 23 (02) : 121 - 131
  • [46] Rare and Serious Adverse Effects of Anti-Tumor Necrosis Factor-Alpha (TNF-α) Agents in Crohn's Disease
    Kim, Sun
    Edelstein, Peter
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (04)
  • [47] Correlation of serum levels of anti-tumor necrosis factor agents with perianal fistula healing in Crohn's disease: a narrative review
    Miranda, Eron Fabio
    Nones, Rodrigo Bremer
    Kotze, Paulo Gustavo
    INTESTINAL RESEARCH, 2021, 19 (03) : 255 - 264
  • [48] The Appropriateness of Concomitant Immunomodulators With Anti-Tumor Necrosis Factor Agents for Crohn's Disease: One Size Does Not Fit All
    Melmed, Gil Y.
    Spiegel, Brennan M.
    Bressler, Brian
    Cheifetz, Adam S.
    Devlin, Shane M.
    Harrell, Laura E.
    Irving, Peter M.
    Jones, Jennifer
    Kaplan, Gilaad G.
    Kozuch, Patricia L.
    Velayos, Fernando S.
    Baidoo, Leonard
    Sparrow, Miles P.
    Siegel, Corey A.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2010, 8 (08) : 655 - 659
  • [49] Multiple sclerosis as an adverse effect of anti-tumor necrosis factor agents: an infrequent but important complication of infliximab in Crohn's disease
    Mir Subias, Alberto
    Garcia-Lopez, Santiago
    Sebastian Torres, Berta
    Ollero Domenche, Leticia
    Garcia Gamez, Andres
    Gomollon, Fernando
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2013, 36 (02): : 81 - 85
  • [50] Adalimumab and Infliximab Are Equally Effective for Crohn's Disease in Patients Not Previously Treated With Anti-Tumor Necrosis Factor-α Agents
    Kestens, Christine
    van Oijen, Martijn G. H.
    Mulder, Charlotte L. J.
    van Bodegraven, Ad A.
    Dijkstra, Gerard
    de Jong, Dirk
    Ponsioen, Cyriel
    van Tuyl, Bas A. C.
    Siersema, Peter D.
    Fidder, Herma H.
    Oldenburg, Bas
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2013, 11 (07) : 826 - 831
12345